Cytokine release syndrome
نویسندگان
چکیده
منابع مشابه
Rituximab and Cytokine Release Syndrome
Rituximab is a biologic agent that is usually well tolerated. With its increasing use for a myriad of rheumatologic and immunologic conditions, post-marketing surveillance has revealed more side effects. Systemic inflammatory response syndrome associated with cytokine release syndrome (CRS) is a very rare entity associated with the use of rituximab and carries a very high morbidity and case fat...
متن کاملEffect of Ganoderma Lucidum on Cytokine Release by Peritoneal Macrophages
Background: The water-soluble extract of Ganoderma lucidum (Reishi) has been used as an immunomodulator to stimulate spleen cells proliferation and cytokine expression. Objective: To investigate the effect of Ganoderma lucidum (G. lucidum) on cytokine production by mice peritoneal macrophages. Methods: Mice peritoneal macrophages were prepared by intra-peritoneal injection of 5 ml cold PBS. Per...
متن کاملCytokine release in sepsis
Despite the advances in the therapeutic approaches, health care protocols and policies, sepsis continues to be an important problem in clinical medicine. High lethality of sepsis cases calls for a detailed and critically important study of the pathophysiology of sepsis. In this review, we discuss pathomechanisms of sepsis and the role of cytokines that are released in sepsis. We propose that th...
متن کاملMechanisms of eosinophil cytokine release.
Human eosinophils have been demonstrated to contain a multitude of cytokines and chemokines that exist pre-formed within these cells. This content of pre-formed cytokines, with diverse potential biologic activities, provides eosinophils with capabilities distinct from most other leukocytes. The localization of pre-formed cytokines within eosinophils is both within specific granules and associat...
متن کاملCytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.
Blinatumomab is a CD19/CD3-bispecific T-cell receptor-engaging (BiTE) antibody with efficacy in refractory B-precursor acute lymphoblastic leukemia. Some patients treated with blinatumomab and other T cell-activating therapies develop cytokine release syndrome (CRS). We hypothesized that patients with more severe toxicity may experience abnormal macrophage activation triggered by the release of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Oncological Sciences
سال: 2018
ISSN: 2452-3364
DOI: 10.1016/j.jons.2018.09.002